Benefits of amitriptyline in relation to interstitial cystitis

Authors

DOI:

https://doi.org/10.56294/saludcyt20241027

Keywords:

Interstitial Cystitis, Amitriptyline, Painful Bladder Syndrome, Treatment, Efficacy

Abstract

Introduction: interstitial cystitis is a clinical syndrome characterized by increased urinary frequency and pelvic pain, primarily affecting women. Two phenotypes of this disease have been identified, each with a different mechanism. Proper diagnosis is essential, as it can be confused with a urinary tract infection. Amitriptyline, a tricyclic antidepressant, has shown benefits in the treatment of interstitial cystitis by acting on symptoms and improving patients' quality of life. Its mechanism of action includes blocking the reuptake of neurotransmitters associated with pain.
Objectives: the main objective of this study is to review the main benefits of amitriptyline in relation to interstitial cystitis, analyzing its efficacy and safety.
Methods: a literature review was conducted using the Prisma method. Clinical trials and systematic reviews addressing the benefits of amitriptyline in patients with interstitial cystitis were included.
Results: after selecting 15 relevant articles, it was found that amitriptyline can reduce symptoms and improve the quality of life of patients with interstitial cystitis. Additionally, a significant improvement was observed in patients treated with amitriptyline compared to other treatments. Amitriptyline demonstrated an anti-inflammatory, nervous system modulating, and urodynamic effect in patients with interstitial cystitis.
Conclusions: amitriptyline may be an effective and safe option in the treatment of interstitial cystitis, improving symptoms and quality of life for patients. It is suggested that this drug may act as a neuromodulator, anti-inflammatory, and urodynamic agent in patients with interstitial cystitis

References

1. Akiyama Y, Luo Y, Hanno PM, Maeda D, Homma Y. Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives. Int J Urol [Internet]. 2020;27(1):491 –503. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1111/iju.14229

2. Garzon S, Laganà AS, Casarin J, Raffaelli R, Cromi A, Sturla D, et al. An update on treatment options for interstitial cystitis. Prz Menopauzalny [Internet]. 2020;19(2):35–43. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258371

3. Ha T, Xu JH. Interstitial cystitis intravesical therapy. Transl Androl Urol [Internet]. 2017;6(I): S171–9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522791/

4. Lopez SR, Mangır N. Current standard of care in treatment of bladder pain syndrome/interstitial cystitis. Ther Adv Urol [Internet]. 2021; 13:1–10. Disponible en: https://journals.sagepub.com/doi/10.1177/17562872211022478

5. Colemeadow J, Sahai A, Malde S. Clinical management of bladder pain syndrome/ interstitial cystitis: A review on current recommendations and emerging treatment options. Res Reports Urol [Internet]. 2020; 12:331–43. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455607/

6. Smith JL: Case of the month. Interstitial cystitis. JAAPA 2004; 17: 48.

7. García, Á. (2020). La amitriptilina puede ser una opción terapéutica efectiva para los pacientes con cistitis intersticial. Para más información, 15, 105-124. Amitriptilina para la fibromialgia en adultos | Cochrane

8. Perez-Marrero R, Emerson LE and Feltis JT: A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 1988; 140: 36.

9. Fernández S, Peláez R, Aguilar JL. Tratamiento farma cológico en el dolor pélvico urogenital crónico: revisión de la evidencia disponible. Rev Soc Esp Dolor 2011; 1: 56-63.

10. Rodríguez, C., Cardenas, M. D., Figueras, M. P., & Lorenzo, I. (2017). Características diferenciales de las intoxicaciones en los pacientes ancianos atendidos en un servicio de urgencias. Emergencias, Pág. (29):335-338.

11. Martínez, M., Sánchez de la Torre, C., Almanza, E., & Anal, J. (2004). Toxicol. 174.

12. Carballido J, Olivier C, Hernández A. Patología inflamatoria e infección del urotelio. Cistitis y cistopatías. Medicina, 7 (1997), pp. 2917

13. Gómez, F. (2014). Actualización del uso de fármacos: categorías de riesgo. Farmacia Hospitalaria, Organo oficial de expresión científica de la sociedad española de Farmacia hospitalaria, Pág. 38(4):364-378.

14. Torres Pizano. Hydroxychloroquine in the treatment of COVID-19 disease: a systematic review and meta-analysis. Med J Indones., 30 (2021), pp. 20-32

15. Jiménez-R. Bimodal distribution of risk for childhood obesity in urban Baja California, Mexico. J Urban Health. 2012;89:628-38

16. Sánchez N. (2004). Toxicol. 174.

17. López-Castillón. A simple estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr. 2003;57: 201-8.

18. Ruiz, O: Hydrodistension under local anesthesia for patients with suspected painful bladder syndrome/interstitial cystitis: Safety, diagnostic potential and therapeutic efficacy. Int J Urol 2009; 16: 947.

19. Díaz, E. (1989). Tricyclic Antidepressants: Contemporary Issues for Therapeutic Practice. The Canadian Journal of Psychiatry, Pág. 34(6), 609– 617. https://doi.org/10.1177/070674378903400622

20. Vargas, F. Hydrodistention plus bladder training frente a hydrodistention for the treatment of interstitial cystitis. Taiwanese J Obstetrics & Gynecology 2012; 51: 591.

Downloads

Published

2024-01-01

How to Cite

1.
Chato-Noroña AP, Galárraga-Pérez EA. Benefits of amitriptyline in relation to interstitial cystitis. Salud, Ciencia y Tecnología [Internet]. 2024 Jan. 1 [cited 2024 Dec. 10];4:1027. Available from: https://sct.ageditor.ar/index.php/sct/article/view/735